Human BioSystems
Human BioSystems:Human BioSystems Submits SB-2 Registration Statement to the SEC for the Exchange of Reg S Shares Into Registered Shares
Corporate-news transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
——————————————————————————
BioSystems Submits SB-2 Registration Statement to the SEC for the Exchange
of Reg S Shares Into Registered Shares
Monday June 5, 7:00 am ET
PALO ALTO, CALIFORNIA–Jun 5, 2006 — Human BioSystems (HBS) (OTC
BB:HBSC.OB – News), a developer of preservation platforms for organs and
other biomaterials, specializing in the development of proprietary above
zero (‘HBS-AZ’) and below zero (‘HBS-BZ’) organ and tissue preservation
systems and methods for preserving blood platelets, announced a proposed
offering of up to 10,500,000 shares of common stock by certain shareholders
who obtained the stock in an earlier exchange offer pursuant to Regulation
S promulgated under the Securities Act of 1933, as amended. HBS has filed
with the Securities and Exchange Commission a registration statement
relating to the proposed offering. HBS will not sell any shares of common
stock in this offering, nor will it receive any proceeds from it.
A registration statement relating to these securities has been filed with
the Securities and Exchange Commission but has not yet become effective.
These securities may not be sold nor may offers to buy be accepted prior to
the time the registration statement becomes effective. This release shall
not constitute an offer to sell or the solicitation of an offer to buy nor
shall there be any sale of these securities in any State in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such State.
HBS is headquartered in Palo Alto, California, with research facilities in
Michigan.
Certain statements contained herein are ‘forward-looking” statements (as
such term is defined in the Private Securities Litigation Reform Act of
1995). Because such statements include risks and uncertainties, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to, results from ongoing research
and development as well as clinical studies, ability to reproduce study
results in humans, failure to obtain regulatory approval for the Company’s
products, if required, failure to develop a product based on the Company’s
technology, failure of any such products to compete effectively with
existing products, the inability to find a strategic partner or to
consummate a relationship with a potential strategic partner on acceptable
terms, and other factors discussed in filings made by the Company with the
Securities and Exchange Commission.
Contact:
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
YES INTERNATIONAL
Rich Kaiser
Investor Relations
(800) 631-8127
rich@yesinternational.com
(c)DGAP 13.06.2006
—————————————————————————
Latest News
Latest Reports
Upcoming Events
No Events found